News and Press Releases
Press releases
Theralase® Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six
Press ReleasePatient Five and Six Demonstrate No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Company Successfully Completes 180 days Follow Up of the Phase Ib Study and Plans Regulatory Filings to Commence a Phase II Clinical Study that...
Theralase® Releases 2Q2018 Financial Statements
Press ReleaseToronto, Ontario – July 26, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment
Press ReleasePatient Five Demonstrates No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Toronto, Ontario – July 16, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage p...
Theralase® Releases AGM Videos
Press ReleaseToronto, Ontario – June 29, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Phot...
Theralase® Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin® Based Photo Dynamic Therapy, in Immune Privileged Sites
Press ReleaseToronto, Ontario – June 22, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours
Press ReleaseToronto, Ontario – June 11, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activat...
Theralase® Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseTheralase Medical and Scientific Advisory Board concluded that the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has met its objectives and unanimously voted for the early termination of the Study...
Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleasePatient Five Shows No Clinical Evidence or Presence of NMIBC at 90 Day Cystoscopy Analysis Patient Six Shows No Clinical Evidence or Presence of NMIBC to Date Toronto, Ontario – April 16, 2018 Theralase Technologies Inc. (“Theralas...
Theralase® Increases Revenue 22% for 2017 Financial Statements
Press ReleaseToronto, Ontario – April 30, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleasePatient Six Demonstrates No Clinical Evidence of NMIBC at 90 Day Cystoscopy Analysis Toronto, Ontario – May 17, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage phar...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
